GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Accounts Payable

Biogen (BUE:BIIB) Accounts Payable : ARS326,048 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Biogen Accounts Payable?

Biogen's Accounts Payable for the quarter that ended in Mar. 2024 was ARS326,048 Mil.

Biogen's quarterly Accounts Payable declined from Sep. 2023 (ARS154,013 Mil) to Dec. 2023 (ARS145,591 Mil) but then increased from Dec. 2023 (ARS145,591 Mil) to Mar. 2024 (ARS326,048 Mil).

Biogen's annual Accounts Payable increased from Dec. 2021 (ARS59,503 Mil) to Dec. 2022 (ARS82,400 Mil) and increased from Dec. 2022 (ARS82,400 Mil) to Dec. 2023 (ARS145,591 Mil).


Biogen Accounts Payable Historical Data

The historical data trend for Biogen's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Accounts Payable Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31,727.83 37,019.76 59,503.31 82,399.97 145,591.30

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97,036.56 106,896.00 154,013.00 145,591.30 326,047.51

Biogen Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


Biogen Accounts Payable Related Terms

Thank you for viewing the detailed overview of Biogen's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BUE:BIIB) Headlines